Financings Roundup
Regentis Raises $10M for Knee Cartilage Regeneration Product
A Series C financing round of $10 million will support clinical studies and commercial launch of Regentis Biomaterials Ltd.'s knee cartilage regeneration product, GelrinC, in Europe, including a sales force and a postmarket study.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.